Literature DB >> 25687724

Study of the concordance between p16 immunohistochemistry and HPV-PCR genotyping for the viral diagnosis of oropharyngeal squamous cell carcinoma.

D Fonmarty1, S Cherrière1, H Fleury2, S Eimer3, C Majoufre-Lefebvre4, V Castetbon1, E de Monès5.   

Abstract

OBJECTIVE: The diagnosis of HPV-related oropharyngeal cancer in clinical practice is based on p16 immunohistochemistry and PCR detection of viral DNA (HPV-PCR). The primary objective of this study was to evaluate the concordance between these 2 diagnostic tests. The secondary objective was to study the clinical characteristics of these patients.
MATERIALS AND METHODS: This single-centre prospective study was conducted between February 2010 and July 2012. Immunohistochemical analysis of p16 and HPV-PCR were performed on tumour biopsies. Concordance was evaluated according to Cohen's kappa coefficient and was interpreted according to the Landis and Koch scale. The patients' clinical data were analysed as a function of the diagnostic test results.
RESULTS: Seventy-one patients were included in this study. The prevalence of HPV was 43.7% according to p16 and 31% according to HPV-PCR. The concordance study revealed a kappa coefficient of 0.615. A tumour of the tonsil or base of the tongue was detected in 100% of p16+/HPV-PCR+ cases. Smoking and alcohol abuse were significantly less frequent among HPV+ patients regardless of the method of detection. These patients were older and presented tumours with a lower grade of histological differentiation.
CONCLUSION: p16 immunohistochemistry or HPV-PCR used alone appear to be insufficient. These results confirm the high prevalence of HPV-related oropharyngeal squamous cell carcinoma (OSCC) and the previously reported specific clinical and histological features, apart from age. It appears essential for future clinical trials to be stratified according to smoking and tumour HPV status, defined by means of reliable virological tests targeting E6/E7 mRNA and no longer a simple positive response to the p16 marker, as is frequently the case at the present time. New tests suitable for use in routine practice therefore need to be developed.
Copyright © 2015 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  HPV; Oropharyngeal cancer; P16; PCR

Mesh:

Substances:

Year:  2015        PMID: 25687724     DOI: 10.1016/j.anorl.2015.01.003

Source DB:  PubMed          Journal:  Eur Ann Otorhinolaryngol Head Neck Dis        ISSN: 1879-7296            Impact factor:   2.080


  8 in total

1.  CD274 (PD-L1), CDKN2A (p16), TP53, and EGFR immunohistochemical profile in primary, recurrent and metastatic vulvar cancer.

Authors:  Sofia Lérias; Susana Esteves; Fernanda Silva; Mário Cunha; Daniela Cochicho; Luís Martins; Ana Félix
Journal:  Mod Pathol       Date:  2019-12-16       Impact factor: 7.842

2.  New cancer cases in France in 2015 attributable to infectious agents: a systematic review and meta-analysis.

Authors:  Kevin David Shield; Claire Marant Micallef; Catherine de Martel; Isabelle Heard; Francis Megraud; Martyn Plummer; Jérôme Vignat; Freddie Bray; Isabelle Soerjomataram
Journal:  Eur J Epidemiol       Date:  2017-12-06       Impact factor: 8.082

Review 3.  Recent Progress in Therapeutic Treatments and Screening Strategies for the Prevention and Treatment of HPV-Associated Head and Neck Cancer.

Authors:  Sonia N Whang; Maria Filippova; Penelope Duerksen-Hughes
Journal:  Viruses       Date:  2015-09-17       Impact factor: 5.048

4.  The Relation of HPV Infection and Expression of p53 and p16 Proteins in Esophageal Squamous Cells Carcinoma.

Authors:  Paula Roberta Aguiar Pastrez; Vânia Sammartino Mariano; Allini Mafra da Costa; Estela Maria Silva; Cristovam Scapulatempo-Neto; Denise Peixoto Guimarães; Gilberto Fava; Said Abdala Zemi Neto; Emily Montosa Nunes; Laura Sichero; Luisa Lina Villa; Kari Juhani Syrjanen; Adhemar Longatto-Filho
Journal:  J Cancer       Date:  2017-04-09       Impact factor: 4.207

Review 5.  Time to change perspectives on HPV in oropharyngeal cancer. A systematic review of HPV prevalence per oropharyngeal sub-site the last 3 years.

Authors:  Linnea Haeggblom; Torbjörn Ramqvist; Massimo Tommasino; Tina Dalianis; Anders Näsman
Journal:  Papillomavirus Res       Date:  2017-05-19

6.  Identifying epigenetic biomarkers of established prognostic factors and survival in a clinical cohort of individuals with oropharyngeal cancer.

Authors:  Ryan Langdon; Rebecca Richmond; Hannah R Elliott; Tom Dudding; Nabila Kazmi; Chris Penfold; Kate Ingarfield; Karen Ho; Andrew Bretherick; Chris Haley; Yanni Zeng; Rosie M Walker; Michael Pawlita; Tim Waterboer; Tom Gaunt; George Davey Smith; Matthew Suderman; Steve Thomas; Andy Ness; Caroline Relton
Journal:  Clin Epigenetics       Date:  2020-06-29       Impact factor: 6.551

Review 7.  Current status of clinical testing for human papillomavirus in oropharyngeal squamous cell carcinoma.

Authors:  Kelly Y Kim; James S Lewis; Zhong Chen
Journal:  J Pathol Clin Res       Date:  2018-09-18

8.  Comparing Outcomes for Patients with Human Papillomavirus (HPV) Type 16 versus Other High-Risk HPV Types in Oropharyngeal Squamous Cell Carcinoma.

Authors:  Rachel F Shenker; Nelson H May; Joshua D Waltonen; Jae Paul Yang; Stacey S O'Neill; Bart A Frizzell; Kathryn M Greven; Ryan T Hughes
Journal:  Head Neck Pathol       Date:  2021-02-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.